Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/s

2012-04-17

Headline: Court allows a generic drugmaker to force correction of an overbroad patent use code, enabling challenge to listings that block FDA approval for non‑patented drug uses.

Holding: The Court held that a generic drugmaker may bring a statutory counterclaim to require a brand to correct or delete an inaccurate use code when the patent does not claim the particular approved method the generic seeks to market.

Real World Impact:

Allows generic makers to force correction of inaccurate use codes.
Enables FDA approval for generics of unpatented drug uses when codes are fixed.
May require litigation, causing delay and expense before approval.

Topics: generic drugs, patent listings, FDA approvals, drug labeling, pharmaceutical competition

Summary

Background

A brand drug company (Novo) sells an FDA‑approved diabetes drug for three uses. A generic company (Caraco) sought to market two of those uses. Brands submit short patent descriptions called “use codes” to the FDA’s Orange Book, and the FDA generally accepts them without judging accuracy. Novo changed its use code to describe all approved uses, which prevented Caraco’s proposed carve‑out label and blocked FDA approval. Caraco sued and filed a statutory counterclaim asking a court to correct Novo’s overbroad use code.

Reasoning

The Court read the statutory counterclaim in the law Congress created to address patent listing problems. It held that the phrase saying a counterclaim may be brought when a “patent does not claim … an approved method of using the drug” can apply to particular methods the generic seeks to market, not only to patents that claim no method at all. The Court also concluded that “patent information submitted … under subsection (b) or (c)” includes use codes because FDA regulations require them. The statute’s remedy to “correct or delete” listings supports allowing correction when a use code misdescribes a patent’s scope.

Real world impact

The decision lets generic companies use the counterclaim to force brands to correct overbroad use codes so the FDA can consider section viii carve‑out labels and potentially approve generics for non‑patented uses. The ruling does not itself resolve patent validity or end litigation; it may require courts to decide whether a use code is inaccurate and can involve litigation and delay.

Dissents or concurrances

Justice Sotomayor concurred. She agreed with the ruling but cautioned the counterclaim can only lessen problems created by broad use codes, may still require costly litigation, and that clearer FDA or Congressional rules would better prevent disputes.